Ratings by HSBC (Rajesh Kumar)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/3/2026 | IQVIA Holdings | IQV | Maintain | Buy (N/A) |
|
Details | ||
| 6/3/2026 | Danaher | DHR | Maintain | Buy (N/A) |
|
Details | ||
| 3/17/2026 | Eli Lilly | LLY | Downgrade | Reduce (Hold) |
985.08 (1112.21) |
12.91% | Details | |
| 3/10/2026 | Pfizer | PFE | Maintain | Buy (N/A) |
|
Details | ||
| 3/10/2026 | Bristol-Myers Squibb Co. | BMY | Maintain | Hold (N/A) |
|
Details | ||
| 3/10/2026 | Biogen | BIIB | Maintain | Reduce (N/A) |
|
Details | ||
| 12/10/2025 | Biogen | BIIB | Downgrade | Reduce (Hold) |
180.44 (197.53) |
9.47% | Details | |
| 12/10/2025 | Abbvie | ABBV | Upgrade | Buy (Hold) |
223.12 (232.00) |
3.98% | Details | |
| 12/1/2025 | IQVIA Holdings | IQV | Maintain | Buy (N/A) |
|
Details | ||
| 12/1/2025 | Danaher | DHR | Maintain | Buy (N/A) |
|
Details | ||
| 10/9/2025 | IQVIA Holdings | IQV | Upgrade | Buy (Hold) |
200.86 (165.03) |
-17.84% | Details | |
| 10/1/2025 | Abbvie | ABBV | Downgrade | Hold (Buy) |
231.54 (232.00) |
0.2% | Details | |
| 8/27/2025 | Eli Lilly | LLY | Upgrade | Hold (Reduce) |
736.03 (985.08) |
33.84% | Details | |
| 4/28/2025 | Eli Lilly | LLY | Downgrade | Reduce (Buy) |
859.73 (736.03) |
-14.39% | Details | |
| 4/28/2025 | Biogen | BIIB | Downgrade | Hold (Buy) |
119.51 (197.53) |
65.28% | Details | |
| 4/25/2025 | IQVIA Holdings | IQV | Downgrade | Hold (Buy) |
147.06 (200.86) |
36.58% | Details | |
| 12/4/2024 | Novartis | NVS | Downgrade | Reduce (Hold) |
104.56 (149.15) |
42.65% | Details | |
| 12/4/2024 | Merck | MRK | Upgrade | Buy (Hold) |
100.61 (115.38) |
14.68% | Details | |
| 12/4/2024 | IQVIA Holdings | IQV | Maintain | Buy (N/A) |
|
Details | ||
| 12/4/2024 | Gilead Sciences | GILD | Maintain | Hold (N/A) |
|
Details | ||
| 6/5/2024 | Abbvie | ABBV | Upgrade | Buy (Hold) |
160.19 (232.00) |
44.83% | Details | |
| 4/4/2024 | UnitedHealth Group | UNH | Upgrade | Hold (Reduce) |
459.74 (407.06) |
-11.46% | Details | |
| 12/18/2023 | UnitedHealth Group | UNH | Downgrade | Reduce (Hold) |
534.24 (407.06) |
-23.81% | Details | |
| 12/18/2023 | Abbvie | ABBV | Downgrade | Hold (Buy) |
154.88 (232.00) |
49.79% | Details | |
| 12/18/2023 | Thermo Fisher Scientific | TMO | New Coverage | Buy (N/A) |
521.52 (464.84) |
-10.87% | Details | |
| 12/18/2023 | Teva Pharma | TEVA | New Coverage | Buy (N/A) |
10.23 (32.22) |
214.96% | Details | |
| 12/18/2023 | Danaher | DHR | New Coverage | Hold (N/A) |
229.25 (178.56) |
-22.11% | Details | |
| 10/27/2023 | Bristol-Myers Squibb Co. | BMY | Upgrade | Hold (Reduce) |
56.61 (54.57) |
-3.6% | Details | |
| 9/15/2023 | Bristol-Myers Squibb Co. | BMY | Maintain | Reduce (N/A) |
|
Details | ||
| 7/14/2023 | Sanofi-Aventis | SNY | New Coverage | Buy (N/A) |
51.83 (41.55) |
-19.83% | Details |
